Replies to post #47141 on Ayala Pharmaceuticals Inc (ADXS)

[mypekeispooped]

"Eight of the 9 patients (89%) are progression-free at a median follow-up of 42 months. These data were accepted and published in the International Journal of Radiation Oncology." I like that part.

[Traderbx]

"Preliminary Stage 1 results from 29 of the planned evaluable patients showed 1 (3.5%) patient had a durable partial response lasting > 6 months (after progression on prior anti-PD-1 therapy) and 7 had stable disease (24%). Disease control rate was 28%. The current Kaplan Meier 6-month PFS estimate is 22%, indicating the trial met the criteria to proceed to Stage 2 of enrollment. "

Does this mean ADXS beat past statistics of 22% in FAWCETT?

[Simple Steve]

Interesting. Results seem good. I wonder if ADXS has decided to shelf this because they know trials cost lots of money and they're trying to stretch out what little money they have and hoping that someone shows interest in partnering with them. Seems to me this drug is promising enough, especially considering it has orphan status, that some BP partner would want to step up and take it. What's sad is that people are dying and these companies are dragging their feet. We need to get these drugs out there.